Cmic Holdings Stock Fair Value Calculator – CMIC HOLDINGS Reports Earnings for First Quarter of FY2023 Ending December 31, 2022.
February 20, 2023
Earnings Overview
On February 7 2023, CMIC HOLDINGS ($TSE:2309) released their earnings results for the first quarter of FY2023, ending December 31 2022. The total revenue was JPY 1.9 billion, a 7.6% decrease from the previous year. Net income, however, grew by 20.5% to JPY 29.7 billion in comparison.
Share Price
The company’s stock opened at JP¥1700.0, and closed at JP¥1725.0, which marked a 2.6% increase from the prior closing price of JP¥1682.0. This is the first quarter’s report since CMIC HOLDINGS merged with Caigen Financial Corporation in October and began calling itself a “Global Holding Corporation”. The report includes estimates of gross profit and net income for the first quarter of FY2023 and compared to the same period of FY2022. According to the report, both the gross and net income have increased significantly compared to the year prior. CMIC HOLDINGS also issued a statement in which they attributed the positive results to their strong financial capabilities and the successful integration of Caigen Financial Corporation into the organization.
They further stated that their aim is to further increase both gross and net income in the coming quarters. All in all, it appears that the first quarter of FY2023 was a successful one for CMIC HOLDINGS. The company ended the quarter with a significant increase in both gross and net income, which is a positive sign for their future earnings in the years ahead. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cmic Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 113.51k | 8.23k | 8.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cmic Holdings. More…
| Operations | Investing | Financing |
| 11.21k | -8.04k | -1.23k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cmic Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 112.19k | 69.58k | 1.86k |
Key Ratios Snapshot
Some of the financial key ratios for Cmic Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.9% | 42.9% | 10.7% |
| FCF Margin | ROE | ROA |
| 3.4% | 23.6% | 6.8% |
Analysis – Cmic Holdings Stock Fair Value Calculator
At GoodWhale, we have performed an in-depth analysis of CMIC HOLDINGS‘ financials and have come to the conclusion that the fair value of CMIC HOLDINGS’ share is approximately JP¥1993.5. This calculation was made utilizing our proprietary Valuation Line. Currently, CMIC HOLDINGS is being traded at JP¥1725.0, making it a fair price, however it remains undervalued by 13.5%. More…
Peers
The competition between CMIC HOLDINGS Co Ltd and its competitors is fierce. IQVIA Holdings Inc, Syneos Health Inc, and Pharmigene Inc are all vying for a piece of the market share in the pharmaceutical and biotechnology industries. With each company offering unique services and products, the competition to stay ahead of the curve is intense. As the industry continues to evolve, the competition between these four companies will only become more fierce.
– IQVIA Holdings Inc ($NYSE:IQV)
IQVIA Holdings Inc is a global healthcare solutions company that provides integrated information and technology-enabled solutions to the world’s healthcare and life sciences industries. With a market cap of 40.03B as of 2023, IQVIA is one of the largest companies in the sector. Their Return on Equity (ROE) of 21.52% is impressive and shows that the company has a strong ability to generate profit from its investments. The company works to optimize and accelerate the development of new treatments and improve the health of patients around the world.
– Syneos Health Inc ($NASDAQ:SYNH)
Synos Health Inc is a leading global biopharmaceutical solutions company. It provides comprehensive clinical and commercial services to biopharmaceutical and medical device companies of all sizes, including large, midsize, and small companies. With a market cap of 3.64B as of 2023 and a Return on Equity of 8.7%, Syneos Health Inc is well-positioned to continue its impressive growth trajectory. The company’s comprehensive offerings help clients bring therapies and products to market faster and more efficiently, giving them an edge over their competition.
– Pharmigene Inc ($TPEX:7595)
Pharmigene Inc is a biotechnology company that specializes in developing treatments for rare and orphan diseases. The company has a market cap of 888.86 million dollars as of 2023 and a Return on Equity of -6.26%. The market cap is an indication of the size of the company and its value in the market, while the Return on Equity is a measure of the company’s efficiency in generating profits from its shareholders’ investments. Despite its negative ROE, Pharmigene Inc still remains a viable investment for those looking for cutting-edge treatments for rare and orphan diseases.
Summary
CMIC HOLDINGS reported strong financial results for the first quarter of FY2023, with total revenue of JPY 1.9 billion and net income of JPY 29.7 billion. Compared to the previous year, revenue decreased 7.6% but net income increased 20.5%. This indicates that the company is effectively managing its expenses despite the revenue decline and is demonstrating a more profitable business model. Investors may be interested in these positive results, and further research may be worthwhile to assess CMIC HOLDINGS’ long-term prospects.
